Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract
NCT ID: NCT00299663
Last Updated: 2012-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2006-02-28
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Because of the burden and severity of invasive GAS infection, the Centers for Disease Control and Prevention (CDC) hosted a meeting in to formulate guidelines for responding to postpartum and postsurgical GAS infections. However, we could not find any recommendations for long-term follow-up of patients who had GAS infection subsequent to delivery or gynaecological procedures, or further recommendations regarding subsequent delivery or gynaecological invasive procedures. It is possible that women who had GAS as a cause of vaginal infection may have a tendency to be carriers of this organism, but this has never been proven. We believe it is of importance to determine if women who have had one infection may be long-term carriers which may pose a risk during future pregnancies.
The objective of the present study is to evaluate the incidence of long term gynaecological carrier state of patients who had GAS invasive infection following delivery, and to provide guidelines for follow-up and treatment of such patients.
The proposed study may answer the question whether this endogenous GAS origin represents chronic GAS carrier state, similar to the known GBS carrier state. As some of these patients had severe infections (sometimes life threatening) a protocol for long-term follow up and management is necessary in case an invasive procedure is done (IUD insertion, endometrial biopsy, curettage or delivery) in order to prevent recurrent infection. The information collected in the study will enable us to afford recommendations for follow up and prophylaxis in the future.
.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District
NCT02528890
The Relationship Between GBS Screening in Pregnant Women Insured in Maccabi Healthcare Services (MHS) and Early-onset Neonatal Disease in Israel
NCT04222907
Invasive Group A Streptococcal Infection
NCT05788861
Severe Group A Streptococcus Infections in Paris, France, 2018-2023
NCT06297122
Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections
NCT02010294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Retrospective study
1. The records of all patients diagnosed with GAS infection/isolation in the past 3 years (2003-2005) will be reviewed. The estimated occurrence of GAS isolation from the genital tract in Hadassah hospital is 15 cases every year (Moses personal communication).
2. Patients' files will be reviewed for demographic and clinical variables associated with the development of GAS infection (age, parity, obstetric history), its clinical course and subsequent progress to septic shock, and the site of GAS isolation (blood, vaginal discharge, wound etc).
3. Additional information will be obtained from the patients in order to evaluate the incidence of gynaecological infections and risk factors for such infections. These include events of pelvic inflammatory disease, contraceptive methods, subsequent deliveries or D\&C (a questionnaire is attached).
4. Vaginal cultures and pharyngeal swabs will be taken from all women with previous gynecological GAS infection/isolation participating in the study, in order to evaluate whether carriage of GAS in the vagina occurs.
2. emm typing Since we have the original isolates from women with invasive disease (those presenting with bacteremia) we will be able to compare the specific type isolate obtained in consequent cultures with the original isolate. Isolates will be compared by several known bacterial attributes such as emm type, T type, and the presence of genes for the different exotoxins. emm typing PCR of streptococcal isolates will be performed as previously described \[11\], according to the recommendations of the Division of Bacterial and Mycotic Diseases, Streptococcus pyogenes emm sequence database (http://www.cdc.gov/ncidod/biotech/strep/doc.htm).
3. Prospective study- In addition to the above patients, women presenting from the beginning of the study for two years, with an isolation of GAS from the vagina (even without overt disease), will be followed in order to evaluate the significance of such isolates. These isolates will be collected for comparison with surveillance cultures which will be taken in the future. Vaginal cultures and pharyngeal swabs will be taken every 2 months during the year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hadassah Medical Organization
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ALLON MOSES
Role: STUDY_DIRECTOR
Hadassah Medical Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
1. Chuang I, Van Beneden C, Beall B, Schuchat A. Population-based surveillance for postpartum invasive group a streptococcus infections, 1995-2000. Clin Infect Dis. 2002:15;35:665-70. 2. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report: group A Streptococcus, 2000. 3. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 1993; 269:390 1. 4. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1 7. 5. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997;46(RR-10):1 55. 6. Prevention of Invasive Group A Streptococcal Infections Workshop Participants .Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis. 2003 15;36:243.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GAS-HMO-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.